Researchers report the development of two new anti-androgen drugs that retain their effectiveness in the face of increased expression of the androgen receptor. Patients with metastatic prostate cancer are normally treated with drugs that antagonize androgen function, but most of these patients progress to a more aggressive form of the disease that is driven by increased expression of the androgen receptor. Both the new drugs bind more tightly to the androgen receptor than does the current clinically used anti-androgen. Both new drugs have shown evidence of effectiveness in mouse models, and one of the drugs has shown effectiveness in the early stages of a human clinical trial. The report of the new drug development will be published in the April 9 issue of Science Express.
Login Or Register To Read Full Story